ArticlePediatric nephrology (Berlin, Germany)2026
Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNephropathy in nail-patella syndrome (NPS) has limited therapeutic options. Progressive nephrotic-range proteinuria often persists despite maximal renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Calcineurin inhibitors such as cyclosporine A (CsA) are unexplored in NPS. We therefore evaluated the efficacy and safety of CsA in a patient with NPS.
methodsA 15-year-old boy with genetically confirmed NPS (novel LMX1B missense variant, c.796T>G, p. W266G) was studied. Clinical, pathological, and follow-up data were analyzed. Bioinformatic screening (GSE12008 dataset) identified LMX1B-regulated podocyte genes. Functional assays (immunofluorescence, dual luciferase reporter, and molecular dynamics analyses) assessed the mutation's impact.
resultsThe patient presented with classical NPS features, including nail dysplasia, limited elbow motion, patellar dysplasia, and proteinuria. Kidney biopsy revealed focal glomeruli immaturity with small foci of foamy cells, diffuse foot process effacement, and heterogeneous glomerular basement membrane (GBM) abnormalities (predominantly thinned with segmental thickening and loosening), demonstrating Alport-like kidney pathology. Despite resistance to RAASi and sodium-glucose cotransporter inhibitor (SGLT2i), CsA therapy for 7 months significantly reduced proteinuria from 3.74 to 0.697 g/24 h, increased serum albumin from 28.8 to 39.4 g/L, and maintained normal serum creatinine (54-63 μmol/L). Immunofluorescence analysis of the patient's kidney tissue indicated reduced expressions of PTPRO, NPHS2, and COL4A3. The W266G mutation severely impaired LMX1B binding to the promoters, reducing the transcriptional activity of PTPRO, NPHS2, and COL4A3.
conclusionsCsA effectively reduced nephrotic-range proteinuria in genetically confirmed NPS, suggesting the therapeutic potential of calcineurin inhibitors in for NPS-associated nephropathy.
Indexed as
Identifiers
41249554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.